Logo image of U.CA

Uranium Participation CO (U.CA) Stock Fundamental Analysis

TSX:U -

13.98
+0.01 (+0.07%)
Last: 2/18/2022, 7:00:00 PM
Fundamental Rating

2

Overall U gets a fundamental rating of 2 out of 10. We evaluated U against 78 industry peers in the Capital Markets industry. U scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. U is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

U had negative earnings in the past year.
U.CA Yearly Net Income VS EBIT VS OCF VS FCFU.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 100M -100M -200M

1.2 Ratios

Industry RankSector Rank
ROA -21.32%
ROE 6.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
U.CA Yearly ROA, ROE, ROICU.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 20 -20 -40

1.3 Margins

Industry RankSector Rank
OM 105.34%
PM (TTM) 106.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
U.CA Yearly Profit, Operating, Gross MarginsU.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 20 40 60 80 100

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, U has less shares outstanding
U has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
U.CA Yearly Shares OutstandingU.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
U.CA Yearly Total Debt VS Total AssetsU.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.2 Solvency

U has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
U.CA Yearly LT Debt VS Equity VS FCFU.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.3 Liquidity

U has a Current Ratio of 4.95. This indicates that U is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.95
Quick Ratio N/A

More info and screens

3

3. Growth

3.1 Past

U shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -166.47%.
The earnings per share for U have been decreasing by -51.28% on average. This is quite bad
U shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -160.16%.
The Revenue has been growing by 22.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-166.47%
EPS 3Y-51.28%
EPS 5YN/A
EPS Q2Q%-85.62%
Revenue 1Y (TTM)-160.16%
Revenue growth 3Y-48%
Revenue growth 5Y22.49%
Sales Q2Q%-84.39%

3.2 Future

The Earnings Per Share is expected to decrease by -29.23% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-52.84%
EPS Next 2Y-39.98%
EPS Next 3Y-37.09%
EPS Next 5Y-29.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
U.CA Yearly Revenue VS EstimatesU.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 0 100M -100M -200M
U.CA Yearly EPS VS EstimatesU.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

U reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 49.84, U can be considered very expensive at the moment.
The average S&P500 Price/Forward Earnings ratio is at 22.76. U is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 49.84
U.CA Price Earnings VS Forward Price EarningsU.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -153.59
U.CA Per share dataU.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A cheap valuation may be justified as U's earnings are expected to decrease with -37.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.98%
EPS Next 3Y-37.09%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for U!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Uranium Participation CO

TSX:U (2/18/2022, 7:00:00 PM)

13.98

+0.01 (+0.07%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners32.17%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.10B
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 49.84
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.87
P/tB N/A
EV/EBITDA -153.59
EPS(TTM)-1.15
EYN/A
EPS(NY)0.28
Fwd EY2.01%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS-0.98
BVpS4.87
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.32%
ROE 6.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 105.34%
PM (TTM) 106.3%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y1%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover-0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.95
Quick Ratio N/A
Altman-Z N/A
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-166.47%
EPS 3Y-51.28%
EPS 5YN/A
EPS Q2Q%-85.62%
EPS Next Y-52.84%
EPS Next 2Y-39.98%
EPS Next 3Y-37.09%
EPS Next 5Y-29.23%
Revenue 1Y (TTM)-160.16%
Revenue growth 3Y-48%
Revenue growth 5Y22.49%
Sales Q2Q%-84.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A